Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU health claims

This article was originally published in The Tan Sheet

Executive Summary

The European Food Safety Authority published its final guidance for applicants on the submission of health claims July 26. The guidance says the application must contain information such as the characteristics of the food for which a health claim is made, a proposal for the wording of the health claim, including the specific conditions for use, all pertinent scientific data, the cause and effect relationship between the consumption of the substance and the claimed effect in humans and more. The pre-submission guidance came out in March (1"The Tan Sheet" March 26, 2007, p. 12). EFSA says 300 comments were received for its draft guidance...

You may also be interested in...



Manufacturers Embrace European Guidance On Health Claims

European health product manufacturers expect "pre-submission guidance" adopted by the European Food Safety Authority on applications for authorizing health claims will benefit the industry without imposing significant cost burdens

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel